Advances in CAR-T and CAR-NK cell therapy in follicular lymphoma: a review.
Engineered immune cell therapies show promise for treating follicular lymphoma, though more clinical testing is needed.
This PubMed-indexed study examined follicular lymphoma (FL) is the most common indolent B-cell non-Hodgkin lymphoma and is characterized by prolonged survival but recurrent relapses. The abstract reports their efficacy, durability, safety, and scalability in FL therefore remain to be established in dedicated clinical studies.
What the study was
- Study design
- Narrative Review
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Transplantation and cellular therapy
Why it surfaced
Conservative triage based on the PubMed abstract: narrative review with direct watchlist relevance; score reflects metadata and abstract-level evidence only.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.